Posted by Michael Wonder on 05 Jun 2024
Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence
5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment of patients 12 years of age and older with completely resected melanoma at high risk of recurrence because BMS did not provide an evidence submission.
NICE will review this decision if BMS decides to make a submission.
